Skip to main content
Erschienen in: Pediatric Cardiology 8/2010

01.11.2010 | Original Article

Plasma Clusterin Levels in Predicting the Occurrence of Coronary Artery Lesions in Patients With Kawasaki Disease

verfasst von: Hong-Ren Yu, Ho-Chang Kuo, Eng-Yen Huang, Chi-Di Liang, Kao-Pin Hwang, I-Chun Lin, Jiunn-Ming Sheen, Tzu-Jou Wang, Chih-Lu Wang, Kuender D. Yang

Erschienen in: Pediatric Cardiology | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

Kawasaki disease (KD) is the leading cause of acquired heart disease during childhood in the developed countries. Coronary artery lesions (CAL) are the major complications of KD. A unique proteomic profiling with increased or decreased fibrinogen, alpha-1-antitrypsin, clusterin, and immunoglobulin free light chains were noted in KD in our previous study. The purpose of this study was to evaluate relations between these biomarkers and CAL in KD and to establish within the markers the appropriate cut-off value with which to predict the occurrence of CAL. A total of 47 KD patients were enrolled, including 14 with CAL and 33 without CAL. Plasma samples from patients with KD before intravenous immunoglobulin administration were indicated for measurement of these biomarkers. A potential relation among CAL, clinical characteristics, and these biomarkers was investigated, and a receiver operating characteristic curve was used to identify a cut-off value of the significant marker that best predicated the occurrence of CAL. Among these biomarkers, only plasma clusterin level was associated with the occurrence of CAL. Using a cut-off value of clusterin <12.0 mg/l, the relative risk for CAL was 4.53-fold (95% confidence interval [CI] 1.060–19.347%, P = 0.014). Results from this study suggest that plasma clusterin level <12.0 mg/l in KD is significantly associated with the occurrence of CAL. Results from this study provide a potential biomarker of KD that may help predict the occurrence of CAL.
Literatur
1.
Zurück zum Zitat Ban JY, Yoon KL, Kim SK, Kang S, Chung JH (2009) Promoter polymorphism (rs3755724, -55C/T) of tissue inhibitor of metalloproteinase 4 (TIMP4) as a risk factor for Kawasaki disease with coronary artery lesions in a Korean population. Pediatr Cardiol 30:331–335CrossRefPubMed Ban JY, Yoon KL, Kim SK, Kang S, Chung JH (2009) Promoter polymorphism (rs3755724, -55C/T) of tissue inhibitor of metalloproteinase 4 (TIMP4) as a risk factor for Kawasaki disease with coronary artery lesions in a Korean population. Pediatr Cardiol 30:331–335CrossRefPubMed
2.
Zurück zum Zitat Biezeveld MH, Kuipers IM, Geissler J, Lam J, Ottenkamp JJ, Hack CE et al (2003) Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Lancet 361:1268–1270CrossRefPubMed Biezeveld MH, Kuipers IM, Geissler J, Lam J, Ottenkamp JJ, Hack CE et al (2003) Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Lancet 361:1268–1270CrossRefPubMed
3.
Zurück zum Zitat Cabana VG, Gidding SS, Getz GS, Chapman J, Shulman ST (1997) Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 42:651–655CrossRefPubMed Cabana VG, Gidding SS, Getz GS, Chapman J, Shulman ST (1997) Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 42:651–655CrossRefPubMed
4.
Zurück zum Zitat Cheung YF, Yung TC, Tam SC, Ho MH, Chau AK (2004) Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis. J Am Coll Cardiol 43:120–124CrossRefPubMed Cheung YF, Yung TC, Tam SC, Ho MH, Chau AK (2004) Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis. J Am Coll Cardiol 43:120–124CrossRefPubMed
5.
Zurück zum Zitat Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, Hsieh KS (2008) Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. Circ J 72:1583–1587CrossRefPubMed Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, Hsieh KS (2008) Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. Circ J 72:1583–1587CrossRefPubMed
6.
Zurück zum Zitat Ishikawa Y, Akasaka Y, Ishii T, Komiyama K, Masuda S, Asuwa N et al (1998) Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol 18:665–672PubMed Ishikawa Y, Akasaka Y, Ishii T, Komiyama K, Masuda S, Asuwa N et al (1998) Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol 18:665–672PubMed
7.
Zurück zum Zitat Jenne DE, Lowin B, Peitsch MC, Böttcher A, Schmitz G, Tschopp J (1991) Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 266:11030–11036PubMed Jenne DE, Lowin B, Peitsch MC, Böttcher A, Schmitz G, Tschopp J (1991) Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 266:11030–11036PubMed
8.
Zurück zum Zitat Kim T, Choi W, Woo CW, Choi B, Lee J, Lee K et al (2007) Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur J Pediatr 166:421–425CrossRefPubMed Kim T, Choi W, Woo CW, Choi B, Lee J, Lee K et al (2007) Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur J Pediatr 166:421–425CrossRefPubMed
9.
Zurück zum Zitat Krijnen PA, Niessen HW (2007) The antiapoptotic protein clusterin protects cardiomyocytes against ischemia-induced cell death. Am J Physiol Heart Circ Physiol 293:H3223–H3224CrossRefPubMed Krijnen PA, Niessen HW (2007) The antiapoptotic protein clusterin protects cardiomyocytes against ischemia-induced cell death. Am J Physiol Heart Circ Physiol 293:H3223–H3224CrossRefPubMed
10.
Zurück zum Zitat Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L et al (2007) The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. Pediatr Allergy Immunol 18:354–359CrossRefPubMed Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L et al (2007) The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. Pediatr Allergy Immunol 18:354–359CrossRefPubMed
11.
Zurück zum Zitat Kuo HC, Wang CL, Liang CD, Yu HR, Huang CF, Wang L et al (2009) Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease. Pediatr Allergy Immunol 20:266–272CrossRefPubMed Kuo HC, Wang CL, Liang CD, Yu HR, Huang CF, Wang L et al (2009) Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease. Pediatr Allergy Immunol 20:266–272CrossRefPubMed
12.
Zurück zum Zitat Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278:11590–11600CrossRefPubMed Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278:11590–11600CrossRefPubMed
13.
Zurück zum Zitat Li Y, Sagar MB, Wassler M, Shelat H, Geng YJ (2007) Apolipoprotein-J prevention of fetal cardiac myoblast apoptosis induced by ethanol. Biochem Biophys Res Commun 357:157–161CrossRefPubMed Li Y, Sagar MB, Wassler M, Shelat H, Geng YJ (2007) Apolipoprotein-J prevention of fetal cardiac myoblast apoptosis induced by ethanol. Biochem Biophys Res Commun 357:157–161CrossRefPubMed
14.
Zurück zum Zitat Newburger JW, Burns JC, Beiser AS, Loscalzo J (1991) Altered lipid profile after Kawasaki syndrome. Circulation 84:625–631PubMed Newburger JW, Burns JC, Beiser AS, Loscalzo J (1991) Altered lipid profile after Kawasaki syndrome. Circulation 84:625–631PubMed
15.
Zurück zum Zitat Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110:2747–2771CrossRefPubMed Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110:2747–2771CrossRefPubMed
16.
Zurück zum Zitat Nishimura S, Zaitsu M, Hara M, Yokota G, Watanabe M, Ueda Y et al (2003) A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. J Pediatr 143:357–362CrossRefPubMed Nishimura S, Zaitsu M, Hara M, Yokota G, Watanabe M, Ueda Y et al (2003) A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. J Pediatr 143:357–362CrossRefPubMed
17.
Zurück zum Zitat Nofech-Mozes Y, Garty BZ (2003) Thrombocytopenia in Kawasaki disease: a risk factor for the development of coronary artery aneurysms. Pediatr Hematol Oncol 20:597–601PubMed Nofech-Mozes Y, Garty BZ (2003) Thrombocytopenia in Kawasaki disease: a risk factor for the development of coronary artery aneurysms. Pediatr Hematol Oncol 20:597–601PubMed
18.
Zurück zum Zitat Ohno T, Igarashi H, Inoue K, Akazawa K, Joho K, Hara T (2000) Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 159:424–429CrossRefPubMed Ohno T, Igarashi H, Inoue K, Akazawa K, Joho K, Hara T (2000) Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 159:424–429CrossRefPubMed
19.
Zurück zum Zitat Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA et al (2010) Neurofilament ELISA validation. J Immunol Methods 352:23–31CrossRefPubMed Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA et al (2010) Neurofilament ELISA validation. J Immunol Methods 352:23–31CrossRefPubMed
20.
Zurück zum Zitat Salo E, Pesonen E, Viikari J (1991) Serum cholesterol levels during and after Kawasaki disease. J Pediatr 119:557–561CrossRefPubMed Salo E, Pesonen E, Viikari J (1991) Serum cholesterol levels during and after Kawasaki disease. J Pediatr 119:557–561CrossRefPubMed
21.
Zurück zum Zitat Schneider N, Weigel I, Werkmeister K, Pischetsrieder M (2010) Development and validation of an enzyme-linked immunosorbent assay (ELISA) for quantification of lysozyme in cheese. J Agric Food Chem 58:76–81CrossRefPubMed Schneider N, Weigel I, Werkmeister K, Pischetsrieder M (2010) Development and validation of an enzyme-linked immunosorbent assay (ELISA) for quantification of lysozyme in cheese. J Agric Food Chem 58:76–81CrossRefPubMed
22.
Zurück zum Zitat Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W et al (2006) Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 13:12–19CrossRefPubMed Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W et al (2006) Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 13:12–19CrossRefPubMed
23.
Zurück zum Zitat Shirasawa T, Miyata M, Eto H, Hamada N, Akasaki Y, Miyauchi T et al (2009) Deficiency of clusterin inhibits neointimal hyperplasia after vascular injury. J Atheroscler Thromb 16:772–781PubMed Shirasawa T, Miyata M, Eto H, Hamada N, Akasaki Y, Miyauchi T et al (2009) Deficiency of clusterin inhibits neointimal hyperplasia after vascular injury. J Atheroscler Thromb 16:772–781PubMed
24.
Zurück zum Zitat Song D, Yeo Y, Ha K, Jang G, Lee J, Lee K et al (2009) Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age. Eur J Pediatr 168:1315–1321CrossRefPubMed Song D, Yeo Y, Ha K, Jang G, Lee J, Lee K et al (2009) Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age. Eur J Pediatr 168:1315–1321CrossRefPubMed
25.
Zurück zum Zitat Yu HR, Kuo HC, Sheen JM, Wang L, Lin IC, Wang CL et al (2009) A unique plasma proteomic profiling with imbalanced fibrinogen cascade in patients with Kawasaki disease. Pediatr Allergy Immunol 20:699–707CrossRefPubMed Yu HR, Kuo HC, Sheen JM, Wang L, Lin IC, Wang CL et al (2009) A unique plasma proteomic profiling with imbalanced fibrinogen cascade in patients with Kawasaki disease. Pediatr Allergy Immunol 20:699–707CrossRefPubMed
Metadaten
Titel
Plasma Clusterin Levels in Predicting the Occurrence of Coronary Artery Lesions in Patients With Kawasaki Disease
verfasst von
Hong-Ren Yu
Ho-Chang Kuo
Eng-Yen Huang
Chi-Di Liang
Kao-Pin Hwang
I-Chun Lin
Jiunn-Ming Sheen
Tzu-Jou Wang
Chih-Lu Wang
Kuender D. Yang
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Pediatric Cardiology / Ausgabe 8/2010
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-010-9769-7

Weitere Artikel der Ausgabe 8/2010

Pediatric Cardiology 8/2010 Zur Ausgabe

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.